UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

Clinical cancer research, 2004-08, Vol.10 (16), p.5367-5374

2004

Volltextzugriff (PDF)

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

Clinical cancer research, 2006-04, Vol.12 (8), p.2468-2475

2006

Volltextzugriff (PDF)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

PloS one, 2015-07, Vol.10 (7), p.e0133133-e0133133

2015

Volltextzugriff (PDF)

The Ratio of Positive to Excised Nodes Identifies High-risk Subsets and Reduces Inter-Institutional Differences in Locoregional Recurrence Risk Estimates in Breast Cancer Patients With 1–3 Positive Nodes: An Analysis of Prospective Data From British Columbia and the M. D. Anderson Cancer Center

International journal of radiation oncology, biology, physics, 2007-05, Vol.68 (1), p.59-65

2007

Volltextzugriff (PDF)

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

The lancet oncology, 2018-01, Vol.19 (1), p.27-39

2018

Volltextzugriff (PDF)

Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer

Journal of clinical oncology, 2003-03, Vol.21 (5), p.851-854

2003

Volltextzugriff (PDF)

Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

Breast cancer research : BCR, 2010-12, Vol.12 Suppl 4 (Suppl 4), p.S14-S14, Article S14

Ragaz, Joseph

2010

Volltextzugriff (PDF)

Abstract P1-10-03: Estrogen and breast cancer benefits: Emerging hormone replacement therapy breast cancer paradigms

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-10-03

2022

Volltextzugriff (PDF)

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

BMC cancer, 2013-01, Vol.13 (1), p.42-42, Article 42

2013

Volltextzugriff (PDF)

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

International journal of cancer, 2014-10, Vol.135 (8), p.1961-1969

2014

Volltextzugriff (PDF)

Radiation impact in breast cancer

Breast cancer research : BCR, 2009-01, Vol.11 Suppl 3 (Suppl 3), p.S14-S14, Article S14

Ragaz, Joseph

2009

Volltextzugriff (PDF)

Abstract PS7-05: Estrogen-based hormone replacement therapy [E-HRT] reduces all-cause, breast cancer, and Alzheimer's dementia mortality

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS7-05-PS7-05

2021

Volltextzugriff (PDF)

Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

JNCI : Journal of the National Cancer Institute, 2005-01, Vol.97 (2), p.116-126

2005

Volltextzugriff (PDF)

Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

Investigational new drugs, 2020-04, Vol.38 (2), p.507-514

2020

Volltextzugriff (PDF)

Interaction of 1970–2010 breast cancer in-situ (brca, DCIS) rates with invasive breast cancer (brcainv) and mortality (brcamor): Comparative analysis of two regions with different screening mammography and therapy guidelines (ScreenMam)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e13069-e13069

2016

Volltextzugriff (PDF)

Abstract P3-07-28: Population-based rates of in-situ breast cancer [DCIS] invasive breast cancer [BrINV], and breast cancer [BrCa] mortality [BrMOR] over time. A case for screening mammography? [ScreenMam]

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P3-P3-07-28

2015

Volltextzugriff (PDF)

Long-term breast cancer outcomes in Canada with special analyses of cancer care access and mortality reduction

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1601-1601

2014

Volltextzugriff (PDF)

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

JNCI : Journal of the National Cancer Institute, 2004-03, Vol.96 (6), p.456-465

2004

Volltextzugriff (PDF)

Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer

The New England journal of medicine, 1997-10, Vol.337 (14), p.956-962

1997

Volltextzugriff (PDF)

Abstract P3-10-02: Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P3-P3-10-02

2015

Volltextzugriff (PDF)

Adjuvant targeted therapy in early breast cancer

Cancer, 2009-03, Vol.115 (6), p.1154-1168

2009

Volltextzugriff (PDF)

Breast cancer incidence among young women of urban China (Shanghai) and in Canada: Implications for prevention

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1576-1576

2014

Volltextzugriff (PDF)

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer: Apatinib in metastatic TNBC

International journal of cancer, 2014-10, Vol.135 (8), p.1961-1969

2014

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(76)
Buchkapitel
(2)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

Humans
(56)
Female
(45)
Science & Technology
(34)
Life Sciences & Biomedicine
(33)
Breast Neoplasms - Drug Therapy
(28)
Oncology
(28)
Breast Cancer
(27)
Middle Aged
(26)
Adult
(22)
Biological And Medical Sciences
(20)
Combined Modality Therapy
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Breast Neoplasms - Pathology
(19)
Medical Sciences
(19)
Tumors
(19)
Breast Neoplasms - Surgery
(18)
Aged
(17)
Chemotherapy
(15)
Breast Neoplasms - Mortality
(14)
Lymphatic Metastasis
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

The Ratio of Positive to Excised Nodes Identifies High-risk Subsets and Reduces Inter-Institutional Differences in Locoregional Recurrence Risk Estimates in Breast Cancer Patients With 1–3 Positive Nodes: An Analysis of Prospective Data From British Columbia and the M. D. Anderson Cancer Center

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer

Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

Abstract P1-10-03: Estrogen and breast cancer benefits: Emerging hormone replacement therapy breast cancer paradigms

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Radiation impact in breast cancer

Abstract PS7-05: Estrogen-based hormone replacement therapy [E-HRT] reduces all-cause, breast cancer, and Alzheimer's dementia mortality

Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

Interaction of 1970–2010 breast cancer in-situ (brca, DCIS) rates with invasive breast cancer (brcainv) and mortality (brcamor): Comparative analysis of two regions with different screening mammography and therapy guidelines (ScreenMam)

Abstract P3-07-28: Population-based rates of in-situ breast cancer [DCIS] invasive breast cancer [BrINV], and breast cancer [BrCa] mortality [BrMOR] over time. A case for screening mammography? [ScreenMam]

Long-term breast cancer outcomes in Canada with special analyses of cancer care access and mortality reduction

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer

Abstract P3-10-02: Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer

Adjuvant targeted therapy in early breast cancer

Breast cancer incidence among young women of urban China (Shanghai) and in Canada: Implications for prevention

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer: Apatinib in metastatic TNBC

Suchergebnisse filtern